These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 7946457)

  • 1. Combination of carmofur and interferon-alpha-2B in advanced gastrointestinal cancer--a phase II pilot study.
    Gröhn P; Helle L; Numminen S; Heinonen E
    Acta Oncol; 1994; 33(6):711-3. PubMed ID: 7946457
    [No Abstract]   [Full Text] [Related]  

  • 2. Palliative treatment for advanced gastrointestinal cancer: is response a suitable end-point?
    Jäger E; Bernard H; Knuth A
    Cancer Treat Rev; 1996 Jan; 22 Suppl A():113-5. PubMed ID: 8625335
    [No Abstract]   [Full Text] [Related]  

  • 3. Combination of 5-fluorouracil and recombinant interferon alpha-2B in advanced gastric cancer. A phase I study.
    Lee KH; Lee JS; Suh C; Lee YS; Min YI; Ahn SH; Park KC; Kim SK; Kim SH
    Am J Clin Oncol; 1992 Apr; 15(2):141-5. PubMed ID: 1553902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of escalating interferon alpha-2a combined with 5-fluorouracil and leucovorin in patients with gastrointestinal malignancies.
    Trudeau M; Zukiwski A; Langleben A; Boos G; Hayden K; Batist G
    Acta Oncol; 1993; 32(5):537-9. PubMed ID: 8217238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic interaction of 5-fluorouracil and interferon alpha-2b with or without folinic acid.
    b1p6uller J; Czejka M
    Med Oncol; 1995 Mar; 12(1):47-53. PubMed ID: 8542247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma.
    Grem JL; McAtee N; Murphy RF; Balis FM; Steinberg SM; Hamilton JM; Sorensen JM; Sartor O; Kramer BS; Goldstein LJ
    J Clin Oncol; 1991 Oct; 9(10):1811-20. PubMed ID: 1919632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of combination therapy with interferon-alpha-2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours.
    Hughes MJ; Kerr DJ; Cassidy J; Soukop M; McGregor K; Blackburn N; Yosef H; Kaye SB
    Ann Oncol; 1996 Feb; 7(2):208-10. PubMed ID: 8777180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multimodal biochemical modulation of 5-fluorouracil by leucovorin, methotrexate, and interferon alpha in patients with advanced colorectal cancer.
    Cascinu S; Alessandroni P; Rossi D; Del Ferro E; Fedeli A; Casadei V; Catalano G
    Cancer Chemother Pharmacol; 1996; 38(4):385-6. PubMed ID: 8674163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study.
    Seymour MT; Johnson PW; Hall MR; Wrigley PF; Slevin ML
    Br J Cancer; 1994 Oct; 70(4):719-23. PubMed ID: 7917927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer.
    Vermeulen PB; Dirix LY; Pelgrims G; Van Oosterom AT
    Cancer; 1995 Aug; 76(3):528-30. PubMed ID: 8625138
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase II trial of 5-fluorouracil and alpha-2b interferon in patients with hormone-refractory metastatic prostate cancer.
    Dreicer R; Forest PK; Williams RD
    Urology; 1994 Sep; 44(3):377-80. PubMed ID: 7521094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer.
    Trudeau M; Zukiwski A; Langleben A; Boos G; Batist G
    Cancer Chemother Pharmacol; 1995; 35(6):496-500. PubMed ID: 7882458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorouracil, high-dose folinic acid, low-dose alpha-2b interferon and dipyridamole in the treatment of advanced colorectal cancer. A pilot study.
    Zaniboni A; Marpicati P; Simoncini E; Montini E; Meriggi F; Arcangeli G; Bonera F; Braga M; Ragni F; Marini G
    J Chemother; 1991 Jun; 3(3):180-2. PubMed ID: 1919656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double 5-fluorouracil modulation with folinic acid and recombinant alpha-2B-interferon. A phase I-II study in metastatic colorectal cancer patients.
    Brunetti I; Falcone A; Bertuccelli M; Cianci C; Ricci S; Conte PF
    Am J Clin Oncol; 1994 Jun; 17(3):210-4. PubMed ID: 8192103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of gastrointestinal and renal adenocarcinomas with interferon-alpha.
    Meadows LM; Lindley C; Ozer H
    Biotherapy; 1992; 4(3):179-87. PubMed ID: 1599801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of [6S]-N5-formyltetrahydrofolic acid on the bioavailability of 5-fluorouracil combined with interferon-alpha-2b.
    Czejka MJ; Schüller J; Fogl U
    Arch Pharm (Weinheim); 1992 Jun; 325(6):373-4. PubMed ID: 1444758
    [No Abstract]   [Full Text] [Related]  

  • 17. A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma.
    Shapiro JD; Harold N; Takimoto C; Hamilton JM; Vaughn D; Chen A; Steinberg SM; Liewehr D; Allegra C; Monahan B; Lash A; Grollman F; Flemming D; Behan K; Johnston PG; Haller D; Quinn M; Morrison G; Grem JL
    Clin Cancer Res; 1999 Sep; 5(9):2399-408. PubMed ID: 10499610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double biochemical modulation of 5-fluorouracil by leucovorin and cyclic low dose interferon alpha 2b in advanced colorectal cancer patients.
    Cascinu S; Fedeli A; Fedeli SL; Catalano G
    Ann Oncol; 1992 Jun; 3(6):489-91. PubMed ID: 1498068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly 5-fluorouracil and interferon-alfa-2b in metastatic cancer.
    Quan WD; Casal R
    Cancer Biother Radiopharm; 1996 Jun; 11(3):187-91. PubMed ID: 10851536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-alpha as second-line treatment of advanced transitional cell cancer of the urothelial tract.
    De Mulder PH; Theodore C; Sella A; Koriakine O; Sternberg CN; Collette L; de Balincourt C
    Ann Oncol; 2000 Nov; 11(11):1391-4. PubMed ID: 11142477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.